249 related articles for article (PubMed ID: 9781748)
1. The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries.
Lagos R; Levine OS; Avendaño A; Horwitz I; Levine MM
Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S139-48. PubMed ID: 9781748
[TBL] [Abstract][Full Text] [Related]
2. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections.
Lagos R; Horwitz I; Toro J; San Martin O; Abrego P; Bustamante C; Wasserman SS; Levine OS; Levine MM
Pediatr Infect Dis J; 1996 Mar; 15(3):216-22. PubMed ID: 8852909
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
[TBL] [Abstract][Full Text] [Related]
4. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens.
Lagos R; Valenzuela MT; Levine OS; Losonsky GA; Erazo A; Wasserman SS; Levine MM
Lancet; 1998 May; 351(9114):1472-6. PubMed ID: 9605803
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
[TBL] [Abstract][Full Text] [Related]
7. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
[TBL] [Abstract][Full Text] [Related]
8. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data.
Heath PT
Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S117-22. PubMed ID: 9781743
[TBL] [Abstract][Full Text] [Related]
9. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile.
Levine OS; Ortiz E; Contreras R; Lagos R; Vial P; Misraji A; Ferreccio C; Espinoza C; Adlerstein L; Herrera P
Am J Epidemiol; 1993 Jun; 137(11):1221-8. PubMed ID: 8322763
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
[TBL] [Abstract][Full Text] [Related]
12. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
[TBL] [Abstract][Full Text] [Related]
13. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
[TBL] [Abstract][Full Text] [Related]
14. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants.
Nohynek H; Gustafsson L; Capeding MR; Käyhty H; Olander RM; Pascualk L; Ruutu P
Pediatr Infect Dis J; 1999 Jan; 18(1):25-30. PubMed ID: 9951976
[TBL] [Abstract][Full Text] [Related]
15.
Slack M; Esposito S; Haas H; Mihalyi A; Nissen M; Mukherjee P; Harrington L
Expert Rev Vaccines; 2020 Oct; 19(10):903-917. PubMed ID: 32962476
[TBL] [Abstract][Full Text] [Related]
16. Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia.
Gessner BD; Sedyaningsih ER; Griffiths UK; Sutanto A; Linehan M; Mercer D; Mulholland EK; Walker DG; Steinhoff M; Nadjib M
Pediatr Infect Dis J; 2008 May; 27(5):438-43. PubMed ID: 18398383
[TBL] [Abstract][Full Text] [Related]
17. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
[TBL] [Abstract][Full Text] [Related]
18. An assessment of the value of Haemophilus influenzae type b conjugate vaccine in Asia.
Miller MA
Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S152-9. PubMed ID: 9781750
[TBL] [Abstract][Full Text] [Related]
19. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
Eskola J; Olander RM; Hovi T; Litmanen L; Peltola S; Käyhty H
Lancet; 1996 Dec 21-28; 348(9043):1688-92. PubMed ID: 8973430
[TBL] [Abstract][Full Text] [Related]
20. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.
Schmitt HJ; von Kries R; Hassenpflug B; Hermann M; Siedler A; Niessing W; Clemens R; Weil J
Pediatr Infect Dis J; 2001 Aug; 20(8):767-74. PubMed ID: 11734739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
